Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for gestational diabetes
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on gestational diabetes or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on gestational diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Oral anti-diabetic agents for women with established diabetes/impaired glucose tolerance or previous gestationaldiabetes planning pregnancy, or pregnant women with pre-existing diabetes. While most guidance recommends the use of insulin in women whose pregnancies are affected by pre-existing diabetes, oral anti-diabetic agents may be more acceptable to women. The effects of these oral anti-diabetic agents on maternal and infant health outcomes need to be established in pregnant women with pre (...) -existing diabetes or impaired glucose tolerance, as well as in women with previous gestationaldiabetes mellitus preconceptionally or during a subsequent pregnancy. This review is an update of a review that was first published in 2010.To investigate the effects of oral anti-diabetic agents in women with established diabetes, impaired glucose tolerance or previous gestationaldiabetes who are planning a pregnancy, or pregnant women with pre-existing diabetes, on maternal and infant health. The use
Oral anti-diabetic pharmacological therapies for the treatment of women with gestationaldiabetes. Gestationaldiabetes mellitus (GDM) is a major public health issue with rates increasing globally. Gestationaldiabetes, glucose intolerance first recognised during pregnancy, usually resolves after birth and is associated with short- and long-term complications for the mother and her infant. Treatment options can include oral anti-diabetic pharmacological therapies.To evaluate the effects of oral (...) women, very low-quality evidence), perineal trauma (RR 0.98, 95% CI 0.06 to 15.62; one study, 375 women, very low-quality evidence) or induction of labour (RR 1.18, 95% CI 0.79 to 1.76; one study, 375 women; very low-quality evidence). No data were reported for development of type 2 diabetes or other pre-specified GRADE maternal outcomes (return to pre-pregnancy weight, postnatal depression). For the infant, there was no evidence of a difference in the risk of being born large-for-gestational age
Treatments for women with gestationaldiabetes mellitus: an overview of Cochrane systematic reviews. Successful treatments for gestationaldiabetes mellitus (GDM) have the potential to improve health outcomes for women with GDM and their babies.To provide a comprehensive synthesis of evidence from Cochrane systematic reviews of the benefits and harms associated with interventions for treating GDM on women and their babies.We searched the Cochrane Database of Systematic Reviews (5 January 2018 (...) (hypertensive disorders of pregnancy, pregnancy-induced hypertension, death or serious morbidity composite, insulin versus oral therapy (development of type 2 diabetes); intensive management versus routine care (IOL, large-for-gestational age); post- versus pre-prandial glucose monitoring (large-for-gestational age). The evidence ranged from moderate-, low- and very low-quality.Currently there is insufficient high-quality evidence about the effects on health outcomes of relevance for women with GDM
Gestationaldiabetes Evidence Maps - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4
Gestationaldiabetes and pregnancy outcomes - a systematic review of the World Health Organization (WHO) and the International Association of Diabetes in Pregnancy Study Groups (IADPSG) diagnostic criteria Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.
Planned birth at or near term for improving health outcomes for pregnant women with gestationaldiabetes and their infants. Gestationaldiabetes is a type of diabetes that occurs during pregnancy. Women with gestationaldiabetes are more likely to experience adverse health outcomes such as pre-eclampsia or polyhydramnios (excess amniotic fluid). Their babies are also more likely to have health complications such as macrosomia (birthweight > 4000 g) and being large-for-gestational age (...) (birthweight above the 90th percentile for gestational age). Current clinical guidelines support elective birth, at or near term in women with gestationaldiabetes to minimise perinatal complications, especially those related to macrosomia.This review replaces a review previously published in 2001 that included "diabetic pregnant women", which has now been split into two reviews. This current review focuses on pregnant women with gestationaldiabetes and a sister review focuses on women with pre-existing
Antenatal dietary supplementation with myo-inositol in women during pregnancy for preventing gestationaldiabetes. Gestationaldiabetes, glucose intolerance with onset or first recognition during pregnancy, is a rising problem worldwide. Both non-pharmacological and pharmacological approaches to the prevention of gestationaldiabetes have been, and continue to be explored. Myo-inositol, an isomer of inositol, is a naturally occurring sugar commonly found in cereals, corn, legumes and meat (...) . It is one of the intracellular mediators of the insulin signal and correlated with insulin sensitivity in type 2 diabetes. The potential beneficial effect on improving insulin sensitivity suggests that myo-inositol may be useful for women in preventing gestational diabetes.To assess if antenatal dietary supplementation with myo-inositol is safe and effective, for the mother and fetus, in preventing gestational diabetes.We searched the Pregnancy and Childbirth Group's Trials Register, ClinicalTrials.gov
Combined diet and exercise interventions for preventing gestationaldiabetes mellitus. Gestationaldiabetes mellitus (GDM) is associated with a wide range of adverse health consequences for women and their infants in the short and long term. With an increasing prevalence of GDM worldwide, there is an urgent need to assess strategies for GDM prevention, such as combined diet and exercise interventions. This is an update of a Cochrane review that was first published in 2015.To assess the effects (...) ); and childhood adiposity (BMI z score) (MD 0.05, 95% CI -0.29 to 0.40; 794 participants; 2 RCTs; Tau² = 0.04; I² = 59%; low-quality evidence). However, there was evidence of less gestational weight gain in the diet and exercise intervention group compared with the control group (mean difference (MD) -0.89 kg, 95% CI -1.39 to -0.40; 5052 women; 16 RCTs; Tau² = 0.37; I² = 43%;moderate-quality evidence). No data were reported for maternal postnatal depression or type 2 diabetes; childhood/adulthood type 2
GestationalDiabetesGestationalDiabetes Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 GestationalDiabetesGestationalDiabetes (...) Aka: GestationalDiabetes II. Epidemiology: Prevalence Overall: 6% of pregnant women in U.S. High risk groups (see below): 14% III. Pathophysiology Pancreatic Beta cell hyperplasia is normal in pregnancy Higher g and postprandial levels Placental hormones increase (esp. third trimester) GestationalDiabetes results when increased beta cell function does not overcome IV. Risk Factors Maternal Age > 35 years old (OR 1.6) of in first degree relative (RR 1.7) >25 kg/m2 (OR 3.2) Weight gain >11 lb (5
Gestationaldiabetes mellitus Gestationaldiabetes mellitus - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search Gestationaldiabetes mellitus Last reviewed: February 2019 Last updated: April 2018 Summary Develops during pregnancy and is usually diagnosed at 24 to 28 weeks of gestation on the basis of elevated plasma glucose levels on glucose tolerance testing. Goal of therapy is to achieve maternal glucose levels (...) that are as close to normal as possible in order to avoid fetal macrosomia and complications. Initial therapy for gestationaldiabetes is usually dietary modification. Insulin is started when acceptable glucose levels cannot be maintained with diet alone. Maternal postnatal testing for diabetes or impaired glucose tolerance is performed at least 6 weeks following delivery. The risk for recurrence of GDM in subsequent pregnancies or progression to type 2 diabetes is high. Definition Gestationaldiabetes mellitus
A randomized clinical trial of exercise during pregnancy to prevent gestationaldiabetes mellitus and improve pregnancy outcome in overweight and obese pregnant women. Obesity and being overweight are becoming epidemic, and indeed, the proportion of such women of reproductive age has increased in recent times. Being overweight or obese prior to pregnancy is a risk factor for gestationaldiabetes mellitus, and increases the risk of adverse pregnancy outcome for both mothers and their offspring (...) . Furthermore, the combination of gestationaldiabetes mellitus with obesity/overweight status may increase the risk of adverse pregnancy outcome attributable to either factor alone. Regular exercise has the potential to reduce the risk of developing gestationaldiabetes mellitus and can be used during pregnancy; however, its efficacy remain controversial. At present, most exercise training interventions are implemented on Caucasian women and in the second trimester, and there is a paucity of studies
Periodontal Disease is a Risk Factor for the Development of GestationalDiabetes Mellitus UTCAT3223, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Periodontal Disease is a Risk Factor for the Development of GestationalDiabetes Mellitus Clinical Question In pregnant women, does having periodontal disease increase the risk of gestationaldiabetes mellitus (GDM)? Clinical Bottom Line Studies have shown that periodontal (...) disease and its inflammatory mediators are associated with an increased risk for the development of gestationaldiabetes. This is based on a meta-analysis of 5,724 pregnant patients including 624 cases of GDM. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Abariga/2016 Females with periodontal disease Meta-Analysis Key results Forty-four articles were reviewed, and 10 studies met the eligibility criteria
Screening and Diagnosis of GestationalDiabetes Mellitus* Screening and Diagnosis of GestationalDiabetes Mellitus | National Guideline Clearinghouse success fail JUL Aug 12 2018 2019 30 Sep 2016 - 13 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving copies of rapidly dying or deleted websites for the sake of history and digital heritage. The group is 100% composed (...) In Username or Email * Password * Remember Me Don't have an account? The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018 because federal funding through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our . Guideline Synthesis Screening and Diagnosis of GestationalDiabetes Mellitus Guidelines Being Compared: The Endocrine Society (Endocr Soc) Diabetes and pregnancy: an Endocrine Society
Different methods and settings for glucose monitoring for gestationaldiabetes during pregnancy. Incidence of gestationaldiabetes mellitus (GDM) is increasing worldwide. Blood glucose monitoring plays a crucial part in maintaining glycaemic control in women with GDM and is generally recommended by healthcare professionals. There are several different methods for monitoring blood glucose which can be carried out in different settings (e.g. at home versus in hospital).The objective (...) , for blood glucose monitoring for women with GDM.Two authors independently assessed study eligibility, risk of bias, and extracted data. Data were checked for accuracy.We assessed the quality of the evidence for the main comparisons using GRADE, for:- primary outcomes for mothers: that is, hypertensive disorders of pregnancy; caesarean section; type 2 diabetes; and- primary outcomes for children: that is, large-for-gestational age; perinatal mortality; death or serious morbidity composite; childhood
The Comparative Effectiveness of Diabetes Prevention Strategies to Reduce Postpartum Weight Retention in Women With GestationalDiabetes Mellitus: The GestationalDiabetes' Effects on Moms (GEM) Cluster Randomized Controlled Trial To compare the effectiveness of diabetes prevention strategies addressing postpartum weight retention for women with gestationaldiabetes mellitus (GDM) delivered at the health system level: mailed recommendations (usual care) versus usual care plus a Diabetes (...) Prevention Program (DPP)-derived lifestyle intervention.This study was a cluster randomized controlled trial of 44 medical facilities (including 2,280 women with GDM) randomized to intervention or usual care. The intervention included mailed gestational weight gain recommendations plus 13 telephone sessions between 6 weeks and 6 months postpartum. Primary outcomes included the following: proportion meeting the postpartum goals of 1) reaching pregravid weight if pregravid BMI <25.0 kg/m(2) or 2) losing 5
Dietary supplementation with myo-inositol in women during pregnancy for treating gestationaldiabetes. Gestationaldiabetes mellitus (GDM) is any degree of glucose intolerance that first presents and is recognised during pregnancy and usually resolves after the birth of the baby. GDM is associated with increased short- and long-term morbidity for the mother and her baby. Treatment usually includes lifestyle modification and/or pharmacological therapy (oral antidiabetic agents or insulin (...) of myo-inositol for the treatment of gestationaldiabetes, with no data to examine the majority of outcomes in this review. There do not appear to be any benefits for the infant associated with exposure to myo-inositol such as reduced risk of being born large-for-gestational age. Although the risk of neonatal hypoglycaemia is reduced for the myo-inositol group, there is evidence of imprecision. Evidence from two studies suggested that myo-inositol was associated with a reduced change in maternal BMI
2016CochraneControlled trial quality: predicted high